1	Low-MBL producing genotypes playing a role on protection to leprosy and its
2	multibacillary forms in a highly endemic area for leprosy in Brazil
3	
4 5 6	Erika M. de Salles ^{a,b,1} , Lívia M. Martins ^{b,1} , Rita de C. M. Escocard ^b , Bruno V. G. Forte ^b , Yonnara E. C. Maciel ^b , Thereza L. Kipnis ^b , Edilbert P. Nahn Jr. ^c , Wilmar D. da Silva ^{b,d,2} , Alba L. Peixoto-Rangel ^{b,2*}
7	
8 9 10	^a lnstituto de Ciências Biomédicas, Departamento de Imunologia, Universidade de São Paulo, São Paulo, SP, Brazil
11 12 13	^b Laboratório de Biologia do Reconhecer, Centro de Biociências e Biotecnologia, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, RJ, Brazil
14 15	^c Faculdade de Medicina de Campos, Campos dos Goytacazes, RJ, Brazil
15 16 17 18	^d Laboratório de Imunoquímica, Instituto Butantan, São Paulo, SP, Brazil
20 21 22 23	Thereza L. Kipnis²: In memoriam : Her recognized visionary academic in <i>M. leprae</i> initiatives stimulated the integration of UENF and its social surroundings. ¹ These authors contributed equally to this work. ² These authors also contributed equally to this work.
24 25 26 27	Running head: MBL2 gene polymorphism and susceptibility to leprosy
28 29 30 31 32 33	[*] Corresponding author Avenida Alberto Lamego, 2000 – Parque California. Campos dos Goytacazes/RJ – Brazil. E-mail: alba@uenf.br Telephone number: +55 (22) 2739-7255
34	
35	
36	
37	

38 Abstract

39

40 The high frequency of *MBL2* mutant alleles found in various human populations suggests 41 that they provide some selective advantage. One of the hypotheses is that MBL deficiency 42 may be protective against intracellular pathogens, including *Mycobacterium leprae*. In this 43 study, we investigated the role of *MBL2* in the susceptibility to leprosy. Single-nucleotide 44 variants (SNV) B (rs1800450) and C (rs1800451) in exon 1 of the MBL2 gene and serum MBL 45 concentrations were assessed in 53 patients with leprosy and 68 healthy controls from 46 southeast Brazil by polymerase chain reaction followed by restriction fragment length 47 polymorphism and commercial capture enzyme-linked immunosorbent assay, respectively. 48 The genotyped SNVs were significantly associated with increased protection against leprosy (OR=0.3757, 95% CI=0.1615¹08740, p=0.0273) and more severe forms, including 49 50 multibacillary (OR=0.3769, 95% CI=0.144720.9818, p=0.0493) and lepromatous (OR=0.2423, 51 95% CI=0.0654720.8968, p=0.0369) leprosy. On the other hand, low-MBL producing 52 genotypes were associated with the protection for leprosy, especially in its more severe 53 forms. Low MBL levels and low MBL producing variants were associated with protection 54 against leprosy and progression to more severe forms of this disease. Moreover, this study 55 highlights MBL as a regulator of immune function in which alterations may affect normal 56 responses to leprosy infection and inflammatory stimuli.

57 Keywords: Leprosy; Mannose binding lectin; Polymorphism; *Mycobaterium leprae;* SNV;
58 Complement System

- 59
- 60

61

63 Introduction

Leprosy is a chronic infectious disease caused by the obligate intracellular bacillus 64 *Mycobacterium leprae* that primarily affects the skin and peripheral nerves.¹ Most 65 66 individuals are inherently resistant to leprosy and only a small group develops the disease 67 after exposure to *M. leprae* for long periods. Leprosy is characterized by a wide spectrum of immunologically-defined clinical manifestations. The most severe manifestation is the 68 69 lepromatous form, characterized by the absence of specific cellular immunity leading to 70 widely disseminated disease and extended multibacillary lesions. The other end of the 71 spectrum is represented by the tuberculoid form, which is associated with a vigorous Th1 response and paucibacillary lesions.^{2,3} Innate immunity molecules such as mannose-binding 72 73 lectin (MBL) play an important role on host defense against infections due to their ability to 74 activate the complement system and mediate the lysis and opsonization of microorganisms, and may be involved in the modulation of the immune response to infection with *M. leprae*.⁴ 75 76 The mannose-binding lectin (MBL) pathway involves a C-type lectin, which binds to 77 mannose-containing carbohydrates in microorganisms. MBL levels are genetically 78 determined and may be associated with increased susceptibility to infection by viruses, bacteria, fungi, and protozoa.^{5, 6, 7} However, it has been proposed that MBL deficiency may 79 80 protect the host against intracellular entry by *M. leprae* by reducing the opsonization 81 through the deposition of multiple C3b fragments on the microbial cell surface, resulting in lower phagocytic uptake of bacilli.^{8, 22} MBL acts as a pattern recognition molecule for a wide 82 83 range of infectious agents, recognizing sugar moieties such as mannose, N-84 acetylglucosamine, fucose, and glucose present on the surface of several microorganisms, leading to their phagocytosis and activation of complement.^{9, 19} 85

4

In humans, the gene encoding *MBL2* is located on the long arm of chromosome 10 86 87 (q11.2-q21) and includes four exons. MBL serum levels are strongly affected by structural 88 mutations in exon 1 and promoter region of the gene. A single-nucleotide variant (SNV) was found at codon 54 (allele B, Gly54Asp) in exon 1 of the *MBL2* gene,¹⁰ and subsequent studies 89 90 have revealed the presence of two SNVs at codons 52 (allele D, Arg52Cys) and 57 (allele C, Gly57Glu).¹¹ The alleles derived from SNVs at codons 52, 54, and 57 are termed MBL-D, MBL-91 92 B, and MBL-C, respectively, and are associated with a significant decrease in MBL levels as compared to levels in individuals carrying both copies of the normal allele, termed MBL-A.^{11,} 93 94 ^{12, 13} In addition, three SNVs (termed "H/L", "Y/X", and "P/Q") in the promoter region affect 95 MBL serum concentration. The combination of SNVs results in three haplotypes (HYPA, LYPA, 96 and LYQA) that are associated with normal MBL levels and four haplotypes (LXPA, LYPB, LYQC, and HYPD) associated with low or very low MBL levels.¹⁴ It is possible that these 97 98 variants have been maintained at high frequencies because they provide some selective advantage to the host.^{9, 11, 15} Thus, MBL variants may be conserved mostly in heterozygous 99 100 individuals. Even though some studies have shown the involvement of the complement 101 system in leprosy, few have investigated the role of *MBL2* gene variants on infection with *M*. 102 *leprae* and disease progression. In addition, the genetic diversity of human populations hints 103 at the existence of yet undescribed point mutations in some polymorphic genes that warrant 104 investigation, particularly those with a putative involvement in infectious diseases. In Brazil, infection with *M. leprae* has been reported in different geographic regions.^{21, 22, 24} However, 105 106 these findings have not been extensively validated. Here we investigated a geographically 107 distinct population from the Southeast Brazil in order to evaluate the role of the MBL2 gene 108 and MBL protein in leprosy susceptibility. The present study provides novel information on

5

109 the association between *MBL2* gene variant and susceptibility to leprosy across the110 spectrum of leprosy forms.

111

112 Material and Methods

113 Subjects

114 Cases and controls were recruited in Campos dos Goytacazes, Rio de Janeiro, 115 southeast Brazil (21° 45′ 15″ S and 41° 19′ 28″ W, 13 m asl). Fifty-three patients with leprosy 116 were selected at the Hansen Health Program of the Campos dos Goytacazes Health 117 Secretariat, a regional reference center for treatment of leprosy. Diagnosis was based on 118 clinical examination and bacilloscopy of suspected tissue lesions. Bacillary lesion counts and 119 associated typical histopathology parameters permit diagnosis and classification of leprosy forms (Table 1).^{16, 17} Healthy controls consisted of 68 unrelated individuals recruited from 120 121 the local blood bank (Table 1). Patients (L) and control subjects (HC) were from the same 122 geographical area. Leprosy patients were grouped according to the World Health 123 Organization (WHO) classification in multibacillary (MB) or paucibacillary (PB) leprosy and 124 the Madrid classification in lepromatous leprosy (LL), dimorph leprosy (DL), indeterminate 125 leprosy (IDL), and tuberculoid leprosy (TL) for the analysis (Table 1). The exclusion criteria for 126 subjects were other infectious or inflammatory disease. Informed consent (written) was 127 obtained from all participants and the study was approved by the local Medical Ethics 128 Committee (n°. 1.687.476).

- 129
- 130
- 131
- 132

	Clinical Groups	Clinical Groups	Ν	Age	Gender
	(WHO)	(Ridley and Joplin)		Mean ± SD	Female/Male
				(Range)	(%)
		Lepromatous	22	45.78 ± 18.81	24 74 /70 26
	Multibacillary	(11)	23	(20-91)	21./4//8.26
	Wattbachary	(/		(20 0 2)	
	(MB)	Dimorph		49.3 ± 14.3	
		(=.)	14	()	50/50
Leprosy		(DL)		(30-75)	
Lepiosy					
(L)					
		Indeterminate	_	30.40 ± 15.7	
	Paucibacillan	(וחו)	5	(10-51)	60.00/40.00
	Faucibacinary			(10-51)	
	(PB)	Tuberculoid		40.1 ± 16.9	
		()	11	(2.22)	36.4/63.6
		(L)		(9-69)	
				45.0±19.2	
Tota			53		35.85/64.15
				(9-91)	
Healthy Controls				35.8±11	
,				_	17.6/82.4
(HC)			68	(19-60)	

133 Table 1: Clinical profile of patients with leprosy.

134

135

136 Serum MBL level measurement

137 Serum MBL concentrations were determined using a commercial capture enzyme-138 linked immunosorbent assay (MBP-oligomer ELISA, Microwell strip version; Antibody Shop, 139 Copenhagen, Denmark). Serum (1:100) was added to ELISA microplates coated with 140 monoclonal antibody against the oligomeric MBL carbohydrate-binding domain. The bound 141 MBL was detected by a second biotin-labeled antibody and streptavidin peroxidase, 142 followed by the addition of tetramethylbenzidine (TMB). Color intensity was read in an ELISA 143 reader at 450 nm (Multiskan EX Primary EIA, Thermo Fisher, Waltham, MA, USA). The serum 144 standard results were used to build a calibration curve. MBL concentrations are defined as

7

low (< 100 ng/ml), intermediate (10021000 ng/ml), and high (< 1000 ng/ml) according to the
kit manufacturer's instructions.

147

148 *MBL2* genotyping

149 The exon 1 region of *MBL2* (codons 54 and 57 for alleles B and C, respectively) was 150 genotyped by allele-specific polymerase chain reaction followed by restriction fragment 151 length polymorphism (PCR-RFLP). The forward and reverse primers used were 5'2 152 AGTCGACCCAGATTGTAGGACAGAG23' and R: 5'2AGGATCCAGGCAGTTTCCTCTGGAA GG23', respectively, as described elsewhere.¹⁸ The PCR was performed in 25-µl volumes containing 153 154 100²500 ng (2 μl) of genomic DNA, 0.5 μl of specific primers (12.5 pmol/ml; Fermentas, 155 Waltham, MA, USA), 10 mM deoxynucleotide triphosphates (Fermentas, USA), 1.25 μ l MgCl₂ 156 (50 mM; Invitrogen, Carlsbad, CA, USA), 2.5 μl 10× PCR buffer (without magnesium), and 1 U 157 of tag platinum polymerase (Invitrogen, USA). The following reaction conditions were used: 158 94 °C for 2 min, 35 cycles at 94 °C for 30 s, followed by annealing at 60 °C for 30 s and 72 °C 159 for 2 min, and a final extension step of 5 min at 72 °C. The PCR products were identified by 160 electrophoresis in 2% (w/v) agarose gel stained with ethidium bromide. The fragment 161 amplified by PCR (349 bp) was digested using *Ban*I and *Mbo*II restriction enzymes to detect B 162 and C alleles. The Ban restriction enzyme cleaved the MBL*A allele into two fragments (260 163 and 89 bp) and the MBL*B allele was not cleaved; *Mbo*II cleaved the MBL*C allele into two 164 fragments (279 and 70 bp). Fragments were visualized by electrophoresis in 8% 165 polyacrylamide gel stained with ethidium bromide.

- 166
- 167

8

169 Statistical analysis

170	MBL levels were compared between leprosy patients and healthy controls using the
171	Kruskal-Wallis test followed by Dunn's or Mann-Whitney tests. The allelic and genotypic
172	frequencies were compared using Fisher's exact test. The associations were represented by
173	odds ratios (ORs) with 95% confidence intervals (CIs). Differences were considered
174	significant at p < 0.05. The analyses were performed using GraphPad Prism™ 5.0 (GraphPad
175	Software, San Diego, CA, USA). Hardy-Weinberg equilibrium (HWE) was calculated for each
176	SNV in a set of unrelated controls with a customized spreadsheet in Microsoft Excel.

177

178 **Results**

179 Serum MBL levels in patients and healthy controls

180 MBL serum levels ranged from 0.0 to 3903.0 ng/ml (median = 1983.0 ng/ml) in HC and 181 0.1 to 3024.8 ng/ml (median = 560.0 ng/ml) in L patients. There were no significant 182 differences between L and HC groups (p = 0.2042) and in the comparison among patients 183 with severe forms of the disease (MB and LL) and patients with less severe forms (p= 0.3588 184 and 0.5678, respectively) (Fig. 1). Leprosy patients were also assessed according to MBL 185 production levels. The frequency of low- (< 100 ng/ml), intermediate- (10021000 ng/ml), and 186 high- (> 1000 ng/ml) MBL producers was similar between groups with different degrees of 187 disease severity (Fig. 1).

188

Figure 1: Serum MBL levels (dot plot graphs), and frequencies (parts of whole graphs) were measured by ELISA and plotted according to the presence or absence of leprosy (A); or according to WHO classification (B) or Madri classification (C). Individuals were considered low producers with up to 100 ng/ml, medium with 100 to 1000 ng/ml and high producers above 1000 ng/ml of MBL in sera.

9

194 Allelic and genotypic distribution of SNV B (rs1800450) and C (rs1800451)

195	Only three individuals in the studied population had the C (rs1800451) allele: one
196	individual with the DL form and two HCs, corresponding to a frequency of 0.025. The B allele
197	(rs1800450) had a frequency of 0.2 in the population. When grouped according to presence
198	or absence of leprosy, the frequencies of alleles B and C in the L and HC groups were 0.08
199	and 0.17, respectively. The presence of allele B was protective for the development of
200	leprosy (OR = 0.375, 95% CI = 0.1567 20.8977 , p = 0.0387) and the progression to
201	multibacillary forms of the disease (OR = 0.348, 95% CI = 0.129820.9704, p = 0.0441) (Table
202	2).
203	

205	Table 2: Allele and genotype distribution in subjects with leprosy and healthy controls relative to the single nucleotide	variants B.
		206

Clinical form	Genotype AA (frequency)	Genotype AB (frequency)	p	OR (95% CI)	Allelle A (frequency)	Allele B (frequency)	р	OR (95% CI)
Lopromotous	20	3	0.0633	0.275	43	3	0.0915	0.3256
Lepromatous	(0.87)	(0.13)		(0.07407 - 1.021)	(0.935)	(0.065)		(0.09319 – 1.138)
Bordorlino	11	3	0.3691	0.5500	25	3	0 5755	0.5600
bordennie	(0.786)	(0.214)		(0.1379 – 2.193)	(0.893)	(0.107)	0.5755	(0.1563 – 2.007)
Indotorminato	5	0	0 1 6 4 4	0.1651	10	0	0 26 80	0.2187
mueterminate	(1)	(0)	0.1044	(0.008751 – 3.116)	(1)	(0)	0.5069	(0.1238 – 3.861)
Tuborguloid	8	3	0 7402	0.6875	19	3	0.7600	0.7368
Tuberculoru	(0.727)	(0.273)	0.7402	(0.1666 – 2.837)	(0.864)	(0.136)	0.7690	(0.2018 – 2.691)
Paucibacilar	13	3	0.2472	0.4231	29	3	0.2989	0.4828
Faucipacital	(0.813)	(0.227)		(0.1096 – 1.163)	(0.906)	(0.094)		(0.1358 – 1.716)
Multibeciler	31	6	0.0441	0.3548	68	6	0.0654	0.4118
withibacilar	(0.838)	(0.162)		(0.1298 – 0.9704)	(0.919)	(0.081)		(0.1602 — 1.059)
Loonaa	44	9	0.0387	0.3750	97	9	0.0578	0.4330
Leprosy	(0.83)	(0.17)		(0.1567-0.8977)	(0.915)	(0.085)		(0.1920 - 0.9763)
Control	44	24			112	24		
Control	(0.647)	(0.353)	-	-	(0.824)	(0.176)	-	-

208	To evaluate the protective role of variants in the <i>MBL</i> gene in the development
209	and severity of leprosy, the frequency of alleles B and C was combined in a group
210	named AO. Overall, MBL variants were associated with increased protection against
211	leprosy (OR = 0.3757, 95% CI = 0.161520.8740, p = 0.0273), and their most severe
212	forms according to WHO (MB: OR = 0.3769, 95% CI = 0.144720.9818, p = 0.0493) and
213	Madrid classifications (LL: OR = 0.2423, 95% CI = 0.0654720.8968, p = 0.0369) (Table
214	${f 3}$). These results show that variants B and C are protective against the development of
215	leprosy, especially in its more severe forms.
216	
217	
218	
219	
220	
221	
222	
223	
224	
225	
226	
227	
228	
229	

Table 3: Allele and genotype distribution in subjects with leprosy and healthy controls relative to the single nucleotide variants B and C
 combined.

へつ	\mathbf{r}
2.1	1
	-

234 235	Clinical form	Genotype AA (frequency)	Genotype A0 (frequency)	p	OR (95% CI)	Allelle A (frequency)	Allele 0 (frequency)	р	OR (95% CI)
236	Lepromatous	20 (0.87)	3 (0.13)	0.0369	0.2423 (0.06547 – 0.8968)	43 (0.935)	3 (0.065)	0.0603	0.2952 (0.08488 – 1.026)
237	Borderline	10 (0.714)	4 (0.286)	0.5583	0.6462 (0.1834 - 2.275)	24 (0.857)	4 (0.143)	0.7885	0.7051 (0.2251 – 2.209)
238	Indeterminate	5 (1)	0 (0)	0.1533	0.1458 (0.007737 – 2.747)	10 (1)	0 (0)	0.2094	0.1986 (0.1127 — 3.499)
230	Tuberculoid	8 (0.727)	3 (0.273)	0.7375	0.6058 (0.1472 – 2.492)	19 (0.864)	3 (0.136)	0.7677	0.6680 (0.1837 - 2.429)
239	Paucibacilar	13 (0.812)	3 (0.188)	0.2415	0.3728 (0.09687 – 1.435)	29 (0.906)	3 (0.094)	0.2972	0.4377 (0.1237 - 1.548)
240	Multibacilar	30 (0.811)	7 (0.189)	0.0493	0.3769 (0.1447 - 0.9818)	67 (0.905)	7 (0.095)	0.0757	0.4420 (0.1818 – 1.075)
241	Leprosy	43 (0.811)	10 (0.189)	0.0273	0.3757 (0.1615 – 0.8740)	96 (0.906)	10 (0.094)	0.0448	0.4407 (0.2022 - 0.9606)
_	Control	42 (0.727)	26 (0.273)	-	-	110 (0.809)	26 (0.191)	-	•

13

242 MBL serum levels and their association with MBL genetic variants

243	MBL serum levels were significantly lower in genotype A0 individuals than in AA
244	individuals ($p = 0.0025$). When comparing A0 and AA genotypes in L and HC subjects, L
245	individuals with A0 genotype had significantly lower MBL serum levels than those with
246	AA genotype (p=0,0021). Thus, the results indicate that carrying the ancestral
247	genotype (AA) is related to the highest levels of MBL, while to have the polymorphic
248	variant (A0) can be associated to lower MBL production.
249	

- 250 Figure 2: MBL production associated with *MBL2* genotypes (A) in all subjects and (B) in leprosy
- 251 patients and healthy control. The levels of MBL were compared with Mann-Whitney test. Significance

252 was considered at p < 0.05, p < 0.01 or p < 0.001 as represented by *, ** and ***, respectively.

253

254 **Discussion**

255 256

In this study, we investigated a geographically distinct population from the 257 258 Southeast Brazil in order to evaluate the role of MBL2 gene and MBL protein in the leprosy susceptibility. We found no significant association between MBL levels and 259 260 leprosy when the analysis did not separate individuals by their genotypes, i.e. 261 considering only the levels of MBL in the patients and controls sera (Fig.1). The normal levels of MBL in serum are very stable,²⁵ but may range from 3 to 50 ng/ml in different 262 263 individuals. Due to this wide variation in MBL levels and since sample size was very 264 small, this dosage shall be further tested in larger samples.

The variation in MBL levels can be explained by the occurrence of four allotypes due to mutations in exon 1 of the gene encoding the MBL polypeptide as well as several variants in the promoter region. In our study, we evaluated the genetic variants

14

268 in exon 1 of MBL2 gene (B and C alleles) and found that B variant (rs1800450) was 269 associated with increased protection against leprosy (OR = 0.375, 95% CI = 270 0.156720.8977, p = 0.0387) and multibacillary forms of this disease (OR = 0.348, 95% CI 271 = 0.1298 0.9704, p = 0.0441), and this effect remained significant even after alleles B 272 and C were combined in a group called A0 (leprosy: OR = 0.3757, p = 0.0273; 273 multibacillary form, MB: OR = 0.3769, p = 0.0493; and lepromatous leprosy, LL: OR =0.2423, p = 0.0369). Our findings are partially similar to those of Sapkota et al.,²² who 274 275 suggested a protective role for MBL deficiency against the development of the more 276 severe multibacillary form of leprosy, but not for leprosy. However, their findings were 277 based on protein levels only, unlike the our study that combined data on MBL levels 278 and *MBL2* variant to define MBL deficiency. Another interesting finding of the current 279 study is the distribution of *MBL2* genotypes (AA and AO): the frequencies of genotypes 280 associated with low and intermediate MBL levels were significantly higher in leprosy 281 (L) patients with AO genotype than with AA genotype (p = 0.0021). This result indicates 282 that genotype AO was associated with significantly decreased risk of leprosy and 283 manifestation of more severe forms of the disease, lending further support to the idea 284 that MBL deficiency is associated with protection against leprosy and the development 285 of multibacillary disease. Pathogen or damage-associated molecular sugar patterns 286 (PAMPs/DAMps) on *M. leprae* are recognized by mannose-binding lectin (MBL) and 287 activate the lectin pathway of complement. Autoactivation of the serine protease 288 MASP-1 is followed by transactivation of MASP-2, cleavage of C2 and C4 and formation 289 of the C3 convertase C2Ac4B. C3 convertase ultimately leads to the insertion of C3b 290 opsonins on the surface of the pathogen (20). Also, increased MBL protein in serum is 291 expected to enhance the uptake of C3b/C4b/ficolin/MBL-opsonized *M. leprae*. Thus,

15

292 MBL genetic variants rs1800450 and rs1800451 herein associated to low MBL levels, 293 may be contributing to reduce complement activation of the lectin pathway and 294 phagocytosis, which could be highly beneficial, protecting against leprosy disease. 295 However, functional investigations on phagocytic efficiency of the associated genetic 296 variants rs1800450 and rs1800451 would help to clarify the role of this protein in the 297 disease. Later, yet unidentified intrinsic pathways protect M. leprae bacilli from macrophage defenses by inhibiting the C5b-C9 membrane lytic complex.²⁰ 298 299 Nevertheless, the molecular mechanisms of immune evasion by *M. leprae* bacilli must 300 be better understood.

Messias-Reason et al.²⁰ showed for the first time an association between low-MBL producing haplotypes/compound genotypes and protection against development of lepromatous and borderline leprosy. However, they also found a significant association between the high-MBL producer haplotype LYPA and both leprosy per se and its lepromatous and borderline forms, a finding similar to those described in our study.

307

308 **Conclusions**

In conclusion, this study supports a pivotal role for the MBL pathway in the susceptibility to leprosy. We showed that MBL genetic variants modulate the immune response in *M. leprae*-affected populations and are probably maintained by balancing selection, supporting previous studies of MBL and leprosy.²¹ MBL seems to play an important role on the immune response to infection with *M. leprae*: low MBL levels

16

and low MBL producing variants were associated with protection against leprosy andprogression to more severe forms of this disease.

Considering the high efficiency of the molecular procedure used to identify MBL haplotypes, further studies are needed to clarify the role of MBL in the fate of infected cells. Investigation involving the role of pattern recognition receptors in recognizing pathogen-associated molecular patterns, certainly will contribute for new insights into the innate immune response in leprosy immunoregulation and may indicate potential new targets for therapeutic intervention.

322

323 Abreviations

324 MBL: mannose binding-lectin; SNV: single nucleotide variant; PCR-RFLP: polymerase 325 chain reaction- restriction fragment length polymorphism; MBP-oligomer: oligomeric 326 MBL carbohydrate-binding domain; ELISA: enzyme linked immunosorbent assay; OR: 327 odd ratio; CI: confidence interval; M. leprae: Mycobacterium leprae; WHO: world 328 health organization; L: leprosy patients; HC: healthy controls; MB: multibacillary 329 patients; PB: paucibacillary patients; LL: lepromatous leprosy; DL: dimorph leprosy; 330 IDL: indeterminate leprosy; TL: tuberculoid leprosy; TMB: tetramethylbenzidine; DNA: 331 deoxyribonucleic acid.

332

333 Ethics approval and consent to participate

The study protocol was approved by The Local Ethic Medical Committee (CAEE n°. 19679119.8.0000.5244). Written informed consents were obtained from the participants and/or yours parents/guardians of the participating children.

17

338 **Consent for publication**

339 Not applicable.

340

341 Availability of data and materials

- 342 The dataset supporting the findings of this article is available from the corresponding
- author upon request.

344

345 Competing interests

346 The authors declare that they have no competing interests.

347

348 Funding

- 349 This project has been supported by Foundation Carlos Chagas Filho Research Support
- of the State of Rio de Janeiro (FAPERJ) APQ-1 E-26/111.196/2014. The funders had no
- role in study design, data collection and analysis, decision to publish, or preparation of
- the manuscript.

353

354 Authors' contributions

EMS, acquisition of data and drafting of manuscript; LMM, analysis and interpretation of data; RCME, acquisition of data; BVGF, acquisition of data; YECM, acquisition of data; TLK, In memoriam; EPNJr, clinical examination of patients; WDS, analysis of data; ALPR, study conception and design, interpretation of data, and drafting of manuscript.

360

361 Acknowledgements

362	We th	ank Hansen Health Program of the Campos dos Goytacazes Health Secretariat					
363	and the dermatologist Edilbert P. Nahn Jr. for their hard work and technical expertise						
364	in sele	cting patients and collecting biological material. We also thank the local Blood					
365	Bank	from Ferreira Machado Hospital, Campos dos Goytacazes medical staff, in					
366	selecti	ng healthy controls and collecting biological material.					
367							
368	Refer	ences					
369 370	1.	Ridley DS, Jopling WH, 1966. Classification of leprosy according to immunity. A five- group system. Int J Lepr Other Mycobact Dis 34: 255-273.					
371 372 373 374	2.	Abulafia J, Vignale RA, 1999. Leprosy: pathogenesis updated. Int J Dermatol 38: 321- 334.					
375 376 377 378	3.	Goulart IM, Penna GO, Cunha G, 2002. Immunopathology of leprosy: the complexity of the mechanisms of host immune response to Mycobacterium leprae. <i>Rev Soc Bras Med Trop 35</i> : 365-375.					
379 380 381 382	4.	Prodinger WM, 1999. Complement receptor type two (CR2,CR21): a target for influencing the humoral immune response and antigen-trapping. <i>Immunol Res 20</i> : 187-194.					
382 383 384 385 386	5.	Das BK, Panda AK, 2015. MBL-2 polymorphisms (codon 54 and Y-221X) and low MBL levels are associated with susceptibility to multi organ dysfunction in P. falciparum malaria in Odisha, India. <i>Front Microbiol</i> 6: 778.					
380 387 388 389 390 391	6.	Yanagisawa K, Ogawa Y, Uchiumi H, Gohda F, Mawatari M, Ishizaki T, Mitsui T, Yokohama A, Handa H, Tsukamoto N, et al., 2015. Gene polymorphisms of mannose- binding lectin confer susceptibility to Pneumocystis pneumonia in HIV-infected patients. J Infect Chemother 21: 769-775.					
392 393 394	7.	Liu L, Ning B, 2015. The role of MBL2 gene polymorphism in sepsis incidence. Int J Clin Exp Pathol 8: 15123-15127.					
395 396 397	8.	Turner MW, 2003. The role of mannose-binding lectin in health and disease. <i>Mol Immunol 40</i> : 423-429.					
398 399 400 401	9.	Garred P, Harboe M, Oettinger T, Koch C, Svejgaard A, 1994. Dual role of mannan- binding protein in infections: another case of heterosis? <i>Eur J Immunogenet 21</i> : 125- 131.					
401 402 403 404	10.	Sumiya M, Super M, Tabona P, Levinsky RJ, Arai T, Turner MW, Summerfield JA, 1991. Molecular basis of opsonic defect in immunodeficient children. <i>Lancet 337</i> : 1569-1570.					

405 406	11.	Lipscombe RJ, Sumiya M, Hill AV, Lau YL, Levinsky RJ, Summerfield JA, Turner MW, 1992. High frequencies in African and non-African populations of independent
407 408		mutations in the mannose binding protein gene. Hum Mol Genet 1: 709-715.
409 410 411 412	12.	Lipscombe RJ, Sumiya M, Summerfield JA, Turner MW, 1995. Distinct physicochemical characteristics of human mannose binding protein expressed by individuals of differing genotype. <i>Immunology 85</i> : 660-667.
413 414	13.	Walport MJ, 2001. Complement. First of two parts. N Engl J Med 344: 1058-1066.
415 416 417 418	14.	Garred P, Thiel S, Madsen HO, Ryder LP, Jensenius JC, Svejgaard A, 1992. Gene frequency and partial protein characterization of an allelic variant of mannan binding protein associated with low serum concentrations. <i>Clin Exp Immunol 90</i> : 517-521.
419 420 421	15.	Davison AR, Kooij R, Wainwright J, 1960. Classification of leprosy. 1. Application of the Madrid classification of various forms of leprosy. <i>Int J Lepr 28</i> : 113-125.
422 423 424 425	16.	World Health Organization, 1998. Model Prescribing Information: Drugs Used in Leprosy. Available at: http://apps.who.int/medicinedocs/pdf/h2988e/h2988e.pdf. Accessed May 23, 2018.
426 427 428 429	17.	Madsen HO, Garred P, Thiel S, Kurtzhals JA, Lamm LU, Ryder LP, Svejgaard A, 1995. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. <i>J Immunol 155</i> : 3013-3020.
430 431 432 433	18.	Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, Willis AC, Eggleton P, Hansen S, Holmskov U, et al., 1997. A second serine protease associated with mannan-binding lectin that activates complement. <i>Nature 386</i> : 506-510.
434 435 436 437	19.	Bonar A, Chmiela M, Rudnicka W, Rozalska B, 2005. Mannose-binding lectin enhances the attachment and phagocytosis of mycobacteria in vitro. <i>Arch Immunol Ther Exp</i> (<i>Warsz</i>) 53: 437-441.
438 439 440 441 442	20.	de Messias-Reason IJ, Boldt AB, Moraes Braga AC, Von Rosen Seeling Stahlke E, Dornelles L, Pereira-Ferrari L, Kremsner PG, Kun JF, 2007. The association between mannan-binding lectin gene polymorphism and clinical leprosy: new insight into an old paradigm. <i>J Infect Dis 196</i> : 1379-1385.
443 444 445 446	21.	Dornelles LN, Pereira-Ferrari L, Messias-Reason I, 2006. Mannan-binding lectin plasma levels in leprosy: deficiency confers protection against the lepromatous but not the tuberculoid forms. <i>Clin Exp Immunol</i> 145: 463-468.
447 448 449 450	22.	Sapkota BR, Macdonald M, Berrington WR, Misch EA, Ranjit C, Siddiqui MR, Kaplan G, Hawn TR, 2010. Association of TNF, MBL, and VDR polymorphisms with leprosy phenotypes. <i>Hum Immunol 71</i> : 992-998.
451 452 453 454 455	23.	Vasconcelos LR, Fonseca JP, do Carmo RF, de Mendonca TF, Pereira VR, Lucena-Silva N, Pereira LM, Moura P, Cavalcanti Mdo S, 2011. Mannose-binding lectin serum levels in patients with leprosy are influenced by age and MBL2 genotypes. <i>Int J Infect Dis 15</i> : e551-557.

- 456 24. Nielsen SL, Andersen PL, Koch C, Jensenius JC, Thiel S, 1995. The level of the serum
 457 opsonin, mannan-binding protein in HIV-1 antibody-positive patients. *Clin Exp*458 *Immunol 100*: 219-222.
- 459
- 460 25. Modlin RL, 2010. The innate immune response in leprosy. *Curr Opin Immunol 22*: 48461 54.

















